Drug Profile
Research programme: orally active thrombin inhibitors - Johnson & Johnson Pharmaceutical Research and Development, LLC/Centocor
Alternative Names: JNJ 6368661; Orally active thrombin inhibitors research programme - 3-Dimensional Pharmaceuticals/CentocorLatest Information Update: 11 Jul 2011
Price :
$50
*
At a glance
- Originator Johnson & Johnson Pharmaceutical Research & Development
- Class
- Mechanism of Action Thrombin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 11 Jul 2011 Discontinued - Preclinical for Thrombosis in USA (PO)
- 22 Dec 2003 Data presented at the 45th Annual Meeting of the American Society of Hematology (ASH-2003) have been added to the pharmacokinetics and Thrombosis pharmacodynamics sections
- 16 Apr 2003 3-Dimensional Pharmaceuticals has been acquired by Johnson & Johnson